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INTRODUCTION
Cardiopulmonary bypass (CPB) is characterized by
systemic endotoxaemia followed by cytokine generation,
including the proinflammatory cytokines tumour necrosis
factor-α (TNF-α), interleukin-1β (IL-1β) and anti-
inflammatory cytokine interleukin-10 (IL-10).1,2 The
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proinflammatory cytokines TNF-α and IL-1β upregulate
neutrophil and endothelial adhesive molecule expression
and enhance neutrophil-endothelial adherence.3–5
Enhanced neutrophil-endothelial adherence is thought to
be responsible for inducing lung and myocardial
reperfusion injury after CPB.6 The elevated systemic level
of these proinflammatory cytokines correlate with
increased morbidity and mortality after CPB.1,2,6 Nitric
oxide (NO) is the main factor that regulates vasomotion,
and its level is closely related to the occurrence of
pulmonary arterial hypertension (PAH),7,8 and can be
expressed by directly activating cyclic guanosine
monophosphate (cGMP).9,10 It has been suggested that
proinflammatory cytokines can increase NO via the
expression of inducible NO synthase (iNOS).11,12
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Furthermore, NO is increased after CPB. Therefore, it
would be helpful to investigate the effects of PAH on
CPB-induced proinflammatory cytokines (IL-1β, TNF-α,
and IL-10) and cGMP (as an indicator of NO).
PATIENTS AND METHODS
Seventy-six patients with heart function classified as New
York Heart Association class III who underwent mitral
and/or aortic valve replacement were studied. The protocol
was approved by the Zhongshan Hospital (Shanghai,
China) institutional review board and informed consent
was obtained from patients. Pulmonary arterial pressure
(PAP) was measured by echocardiography before surgery
for each patient. Based on the PAP, the patients were
divided into two groups (cut-off level = 50 mmHg): Group
A with PAP < 50 mmHg (mean = 28.6 ± 9.1 mmHg) and
Group B with PAP ≥ 50 mmHg (mean = 65.8 ± 10.2
mmHg) (Table).
Surgical procedures were performed as routine general
anaesthesia and CPB. Centrifugal pumps and membrane
oxygenators were used for all patients. CPB was performed
with moderate hypothermia (27°–29°C) and moderate
blood dilution (hematocrit: 23%–27%). The activated
clotting time was maintained at greater than 480 seconds.
Blood flow rate ranged from 50–70 ml/kg. Cardioplegic
cold blood (4:1) was administered into the root of aorta or
into the left and right sinuses of the coronary arteries.
Blood samples were taken via the radial artery before
surgery (as baseline), at weaning from CPB and 24 hours
after CPB to measure the concentrations of IL-1β, TNF-α,
IL-10 and cGMP. The blood samples (collected in 20-ml
tubes) were immediately taken to the laboratory and
centrifuged at 4,000 rpm for 20 minutes. The plasma was
then separated and frozen at –70°C for future use. The
reagents for IL-1β, TNF-α and IL-10 were provided by
DIACLONE (France). The levels of IL-1β, TNF-α and IL-10
were determined by enzyme-linked immunosorbent assay
(ELISA) according to the manufacturer’s procedure. The
reagents for cGMP were provided by Sigma Company (St
Louis, MO, USA), and cGMP was assayed using a 125I-
cGMP radio-immunoassay method.13
STATISTICAL ANALYSIS
All data are given as mean plus or minus standard error
of the mean (SEM). The level of statistical significance
(p < 0.05) was tested using Student’s t test on paired data.
RESULTS
Clinical variables
All patients selected suffered from rheumatic heart
disease and underwent mitral and/or aortic valve
replacement. The demographic and perioperative data
are listed in the Table. Except for PAP, there were no
significant differences between the two groups related to
age, weight, ejection fraction, cross-clamping time or
CPB.
Perioperative changes in IL-1β
The IL-1β level of Group B (16.8 pg/ml) was higher
than that of Group A (10.2 pg/ml) at baseline (p < 0.05).
Though the IL-1β level of both groups increased
significantly after CPB (p < 0.01), it rose significantly
higher in Group B (34.8 pg/ml) than in Group A (25.7 pg/ml)
(p < 0.05) (Figure 1).
Perioperative changes in TNF-α
The TNF-α level of Group A rose slightly after CPB
(16 pg/ml to 19.7 pg/ml), while the TNF-α level of Group
Table. Demographic and perioperative data
Cases Sex (M/F) Age (y) Weight (kg) EF (%) T-CC (min) T-CPB (min)
Group A 46 30/16 47.5 ± 11.4 57.2 ± 9.5 55.5 ± 8.4 65.8 ± 18.2 120.2 ± 30.4
Group B 30 15/15 43.5 ± 10.8 56.7 ± 9.4 49.4 ± 7.8 64.0 ± 18.6 115.8 ± 26.4
M/F = male/ female; EF = ejection fraction; T-CC = time of cross-clamping; T-CPB = time of cardiopulmonary bypass.
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B  was higher at baseline, and much higher after CPB
(25.3 pg/ml to 133.6 pg/ml) (p < 0.01). The TNF-α
differences between the two groups during the
perioperative period were significant (p < 0.01) (Figure 2).
Perioperative changes in IL-10
The IL-10 level of Group B (6.2 U/L) was lower than
that of Group A (10.3 U/L) at baseline (p < 0.05). The IL-
10 levels of both groups decreased after CPB (p < 0.05)
and tended to recover within 24 hours after CPB. The IL-
10 levels of the two groups after CPB were significantly
different (p < 0.05) (Figure 3).
Perioperative changes in cGMP
The cGMP level of Group B (4.1 pmol/ml) was lower
than that of Group A at baseline (6.1 pmol/ml) (p < 0.01).
Figure 1. Change in IL-1β (pg/ml). CPB = cardiopulmonary bypass.
Comparison vs before operation: ** p < 0.01
Comparison vs Group A: #p < 0.05
Figure 2. Change in TNF-α (pg/ml). CPB = cardiopulmonary bypass.
Comparison vs before operation: ** p < 0.01
Comparison vs Group A: ## p < 0.01
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Though the cGMP levels of both groups decreased
significantly after CPB (p < 0.01), they returned to baseline
in Group A (p < 0.05) after 24 hours. The cGMP levels of
the two groups after CPB were significantly different
(p < 0.01) (Figure 4).
DISCUSSION
PAH is an important factor for morbidity and mortality
during the perioperative period of cardiac surgery,14 and
it is suggested that up to 58% of early postoperative
mortality is associated with PAH.15 CPB can aggravate
PAH by the formation of emboli, along with increasing
thromboxane and induction of the inflammatory response
by activating complement and leukocytes, and expressing
adherent cytokines.16,17
More attention has been drawn to study the
inflammatory response during CPB.1–3,17 CPB is responsible
for a systemic inflammatory response, which influences
the patient’s recovery after surgery, especially in infants
and neonates.18 The cytokines released during CPB include
IL-1β, TNF-α and IL-10. IL-1β and TNF-α can accelerate the
Figure 3. Change in IL-10 (U/L). CPB = cardiopulmonary bypass.
Comparison vs before operation: * p < 0.05
Comparison vs Group A: # p < 0.05
Figure 4. Change in cGMP (pmol/ml). CPB = cardiopulmonary bypass.
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inflammatory response, while IL-10 plays a protective role
by suppressing inflammatory cytokines.19–21
The mechanism of lung failure after cardiac surgery
remains to be defined. Understanding of the factors that
control pulmonary vasomotion and the role of NO have
increased greatly. NO is the main factor that regulates
pulmonary vascular tone.8,9 Its concentration is closely
related to the occurrence of PAH. Due to the fact that it is
difficult to measure the NO concentration in the body, we
measured the cGMP concentration. cGMP level is closely
related to NO level.10,11
At baseline, the IL-1β and TNF-α levels in Group A
were lower than those in Group B, while the IL-10 level
in Group A was higher than that in Group B. This suggests
that the balance between proinflammatory and anti-
inflammatory cytokines at baseline is different among
patients with different PAPs. At baseline, patients with
PAH may suffer from increased production of IL-1β, TNF-α
and decreased production of IL-10. These baseline
differences may be the result of abnormally functioning
pulmonary arterial endothelium in patients with PAH.
Patients with PAH have decreased expression of NOS,
which results in decreased release of NO.22 Decreased
NO may contribute to the increased levels of pro-
inflammatory cytokines. The increased proinflammatory
cytokines also may be related to the pathology of patients
undergoing valve replacement surgery and may be
responsible for the lower ejection fraction in Group B. We
suggest that the balance between proinflammatory
response and anti-inflammatory response, which may be
important for the clinical outcome, could be different in
patients with PAH.
The cytokines IL-1β, TNF-α and IL-10 of both groups
rose or decreased significantly after CPB (except for TNF-α
of Group A). These changes are related to CPB.19–21 The
interaction between blood and synthetic surfaces during
CPB results in the activation of complement and the
coagulation system, neutrophils and leukocytes16,17, 23–25
and induces systemic proinflammatory cytokines2,19–21,26
IL-1β and TNF-α of Group B rose significantly compared
with group A after CPB. We believe that IL-1β and TNF-α
are more highly expressed after induction in patients with
PAH after CPB. Increased TNF-α may contribute to
myocardial dysfunction and haemodynamic instability
following CPB.27,28 The IL-10 level of Group A remained
higher than that of Group B after CPB. We believe that the
aggravated inflammatory reaction consumes more IL-10
in patients with PAH. The balance of inflammatory and
anti-inflammatory reactions is upset and is liable to
aggravate the inflammatory reaction. The increased levels
of IL-1β and TNF-α result in overexpression of adhesion
molecules such as intercellular adhesion molecule-1,
vascular cell adhesion molecule-1 and endothelial
leukocyte adhesion molecule-1,3–5 which promote
leukocyte adhesion, filtration and transmigration, leading
to vascular damage.29,30
The level of cGMP was significantly lower in Group B
at baseline which implies that the endogenous NO,
produced by constitutive NOS, is lower in patients with
PAH. cGMP was much lower in Group B after CPB
compared to Group A. This may show that NO is produced
less after CPB in patients with PAH. Research suggests that
NO production significantly increases during and after
CPB and is induced by proinflammatory cytokines via the
expression of iNOS,12,31 especially in the lungs and
airways.32,33 The decrease in NO found in our study may
have contributed to the decreased expression of NOS as
a consequence of PAH.22
Based on our study, it appears that the baseline level
of proinflammatory cytokines IL-1β and TNF-α are higher
and the anti-inflammatory cytokine IL-10 is lower in
patients with PAH. The baseline level of cGMP was also
lower in this group of patients. The production of systemic
proinflammatory cytokines IL-1β and TNF-α was highly
expressed and the anti-inflammatory cytokine IL-10 was
less expressed in patients with PAH compared to patients
with normal PAP after CPB. Decreased production of
cGMP was also observed in this group of patients. These
circumstances may be responsible for postoperative organ
dysfunction and morbidity and mortality, especially in
patients with PAH. Anti-inflammatory therapy may be a
potential method to treat PAH during the perioperative
period of cardiac surgery.
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